Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.88 |
| ▸ | LMNA | P02545 | 1/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | PDE5A | O76074 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.48 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.48 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 9/20 | 0.45 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.43 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2719029 | 0.95 | GPR35 (0.79) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL29352570 | 0.94 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL3865 | 0.94 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL29353205 | 0.94 | GPR35 (1.00) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL8662365 | 0.93 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL8199 | 0.93 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL318268 | 0.93 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| Cromolyn SCHEMBL4108171 | 0.93 | GPR35 (0.97) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11175797 | 0.91 | GPR35 (0.88) | GPR35LMNATDP1MEN1KMT2A | |
| SCHEMBL11253121 | 0.91 | GPR35 (0.93) | GPR35LMNATDP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226017-A1 | METHODS OF TREATING A CORONAVIRUS INFECTION | MASSACHUSETTS GEN HOSPITAL (US) | 2023-07-20 | — | — | US | disclosed |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | THE GENERAL HOSPITAL CORPORATION (US) | 2023-06-20 | — | — | US | disclosed |
| US-20230149345-A1 | METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS | THE GENERAL HOSPITAL CORPORATION | 2023-05-18 | — | — | US | disclosed |
| US-9233169-B2 | Oligomer-bis-chromonyl compound conjugates | NEKTAR THERAPEUTICS (US) | 2016-01-12 | — | — | US | disclosed |
| US-9095621-B2 | Oligome-bis-chromonyl compound conjugates | NEKTAR THERAPEUTICS (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150157734-A1 | OLIGOMER-BIS-CHROMONYL COMPOUND CONJUGATES | NEKTAR THERAPEUTICS | 2015-06-11 | — | — | US | disclosed |
| WO-2014115098-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND INFLAMMATION | KANDULA MAHESH (IN) | 2014-07-31 | — | — | WO | disclosed |
| US-8088935-B2 | Compounds and methods for the treatment of asthma | IRONWOOD PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110112183-A1 | Oligomer-Bis-Chromonyl Compound Conjugates | NEKTAR THERAPEUTICS | 2011-05-12 | — | — | US | disclosed |
| US-20070249644-A1 | Compounds and methods for the treatment of asthma | MICROBIA, INC. (US) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157734-A1 | OLIGOMER-BIS-CHROMONYL COMPOUND CONJUGATES | SLC10A2, SLC10A1, XPO5 | GPR35 1039/4885LMNA 3732/4885TDP1 2608/4885 |
| US-20110112183-A1 | Oligomer-Bis-Chromonyl Compound Conjugates | SLC10A2, SLC10A1, XPO5 | GPR35 1039/4885LMNA 3732/4885TDP1 2608/4885 |
| US-11679095-B2 | Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases | CD68, PRNP, HTT | GPR35 1528/4885LMNA 755/4885TDP1 3376/4885 |
| US-20070249644-A1 | Compounds and methods for the treatment of asthma | NOS2, PTGIS, NOS1 | GPR35 1145/4885LMNA 3052/4885TDP1 3476/4885 |
| US-20230149345-A1 | METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS | C3AR1, IL5, C5 | GPR35 359/4885LMNA 3678/4885TDP1 4796/4885 |
| US-20230226017-A1 | METHODS OF TREATING A CORONAVIRUS INFECTION | CPA3, CMA1, ACE2 | GPR35 1712/4885LMNA 2521/4885TDP1 3569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.